329 related articles for article (PubMed ID: 23815021)
1. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
4. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
5. Novel pharmacological targets for the treatment of Parkinson's disease.
Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
[TBL] [Abstract][Full Text] [Related]
6. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Thobois S; Guillouet S; Broussolle E
Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: diagnosis and treatment.
Rao SS; Hofmann LA; Shakil A
Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
[TBL] [Abstract][Full Text] [Related]
8. Modulation of endoplasmic reticulum stress in Parkinson's disease.
Tsujii S; Ishisaka M; Hara H
Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
[TBL] [Abstract][Full Text] [Related]
9. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
10. Puerarin protects dopaminergic neurons in Parkinson's disease models.
Zhang X; Xiong J; Liu S; Wang L; Huang J; Liu L; Yang J; Zhang G; Guo K; Zhang Z; Wu P; Wang D; Lin Z; Xiong N; Wang T
Neuroscience; 2014 Nov; 280():88-98. PubMed ID: 25218963
[TBL] [Abstract][Full Text] [Related]
11. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
12. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
Albrecht S; Buerger E
Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
[TBL] [Abstract][Full Text] [Related]
13. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of Parkinson's disease.
Singh N; Pillay V; Choonara YE
Prog Neurobiol; 2007 Jan; 81(1):29-44. PubMed ID: 17258379
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
[TBL] [Abstract][Full Text] [Related]
18. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Olanow CW
Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
